Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The role of melatonin on miRNAs modulation in triple-negative breast cancer cells

Full text
Ferreira, Livia C. [1] ; Orso, Francesca [2] ; Dettori, Daniela [2] ; Lacerda, Jessica Z. [1] ; Borin, Thaiz F. [3] ; Taverna, Daniela [2] ; Zuccari, Debora A. P. C. [1, 4]
Total Authors: 7
[1] Univ Estadual Paulista, Dept Biol, Sao Jose Do Rio Preto, SP - Brazil
[2] Univ Torino, Mol Biotechnol Ctr MBC, Dept Mol Biotechnol & Hlth Sci, Turin - Italy
[3] Augusta Univ, Dept Biochem & Mol Biol, Tumor Angiogenesis Lab, Augusta, GA - USA
[4] Fac Med Sao Jose do Rio Preto, Dept Mol Biol, Sao Jose Do Rio Preto, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: PLoS One; v. 15, n. 2 FEB 3 2020.
Web of Science Citations: 1

Melatonin, a hormone secreted by pineal gland, exerts antimetastatic effects by reducing tumor cell proliferation, migration and invasion. MicroRNAs (miRNAs) are small, non-coding RNAs that play a crucial role in regulation of gene expression and biological processes of the cells. Herein, we search for a link between the tumor/metastatic-suppressive actions of melatonin and miRNA expression in triple-negative breast cancer cells. We demonstrated that melatonin exerts its anti-tumor actions by reducing proliferation, migration and c-Myc expression of triple negative breast cancer cells. By using Taqman-based assays, we analyzed the expression levels of a set of miRNAs following melatonin treatment of triple negative breast cancer cells and we identified 17 differentially expressed miRNAs, 6 down-regulated and 11 up-regulated. We focused on the anti-metastatic miR-148b and the oncogenic miR-210 both up-regulated by melatonin treatment and studied the effect of their modulation on melatonin-mediated impairment of tumor progression. Surprisingly, when miR-148b or miR-210 were depleted in triple-negative breast cancer cells, using a specific miR-148b sponge or anti-miR-210, melatonin effects on migration inhibition and c-myc downregulation were still visible suggesting that the increase of miR-148b and miR-210 expression observed following melatonin treatment was not required for the efficacy of melatonin action. Nevertheless, ours results suggest that melatonin exhibit a compound for metastatic trait inhibition, especially in MDA-MB-231 breast cancer cells even if a direct link between modulation of expression of certain proteins or miRNAs and melatonin effects has still to be established. (AU)

FAPESP's process: 15/04780-6 - Melatonin and miRNAs in triple negative breast cancer
Grantee:Debora Aparecida Pires de Campos Zuccari
Support Opportunities: Regular Research Grants